登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C17H14F3N3O2S
化学文摘社编号:
分子量:
381.37
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
grade
pharmaceutical primary standard
API family
celecoxib
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
SMILES string
Cc1ccc(cc1)-c2cc(nn2-c3ccc(cc3)S(N)(=O)=O)C(F)(F)F
InChI
1S/C17H14F3N3O2S/c1-11-2-4-12(5-3-11)15-10-16(17(18,19)20)22-23(15)13-6-8-14(9-7-13)26(21,24)25/h2-10H,1H3,(H2,21,24,25)
InChI key
RZEKVGVHFLEQIL-UHFFFAOYSA-N
Gene Information
human ... PTGS2(5743)
General description
本品按现行药典规定交付。所有为支持本产品而提供的信息，包括SDS和任何产品信息单均由药典颁发机构制定并发布。如需进一步信息和支持，请访问现行药典网站。
Application
塞来昔布EP参考标准品的预期用途是欧洲药典规定的实验室测试。
Biochem/physiol Actions
塞来昔布是一种非甾体类抗炎药 (NSAID) 和环氧化酶-2 (COX-2) 选择性抑制剂。
塞来昔布是一种非甾体类抗炎药 (NSAID) 和环氧化酶-2 (COX-2) 选择性抑制剂。塞来昔布对 COX-2 的选择性至少是 COX-1 的 10-20 倍。
Packaging
本品按照现行药典要求提供。有关当前单位数量，请见EDQM 参考目录。
Other Notes
可能适用相应的销售限制。
Still not finding the right product?
Explore all of our products under 塞来昔布
signalword
Danger
hcodes
Hazard Classifications
Aquatic Chronic 1 - Repr. 1B - STOT RE 2
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Verena Jendrossek
Cancer letters, 332(2), 313-324 (2011-02-25)
Celecoxib is a paradigmatic selective inhibitor of cyclooxygenase-2 (COX-2). This anti-inflammatory drug has potent anti-tumor activity in a wide variety of human epithelial tumor types, such as colorectal, breast, non-small cell lung, and prostate cancers. Up to now, the drug
Axel H Schönthal et al.
Expert opinion on investigational drugs, 17(2), 197-208 (2008-01-31)
Celecoxib is an NSAID that was developed as a selective inhibitor of COX-2 and approved by the FDA for the treatment of various forms of arthritis and the management of acute or chronic pain. In addition, it was more recently
Paul L McCormack
Drugs, 71(18), 2457-2489 (2011-12-07)
Celecoxib (Celebrex®) was the first cyclo-oxygenase (COX)-2 selective inhibitor (coxib) to be introduced into clinical practice. Coxibs were developed to provide anti-inflammatory/analgesic activity similar to that of nonselective NSAIDs, but without their upper gastrointestinal (GI) toxicity, which is thought to
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| Y0001445 | 04061837584572 |